Retrospective Study
Copyright ©The Author(s) 2023.
World J Diabetes. Aug 15, 2023; 14(8): 1271-1279
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1271
Table 1 Clinical effects
Group
Number of cases
Invalid, n (%)
Valid, n (%)
Excellent, n (%)
Total effective rate (%)
Control group6514 (21.54)41 (63.08)10 (15.38)78.46
Observation group654 (6.15)41 (63.08)20 (30.77)93.85
χ2 value8.88
P value0.04
Table 2 Comparison of best-corrected visual acuity before and after treatment
GroupNumber of casesBCVA
Prior treatment
One month of treatment
Three months of treatment
Treatment for 6 mo
Control group650.07 ± 0.020.22 ± 0.0810.30 ± 0.161,20.49 ± 0.201,2,3
Observation group650.07 ± 0.020.21 ± 0.0610.44 ± 0.161,20.62 ± 0.221,2,3
t value1.224-5.221-6.804-4.439
P value0.223< 0.001< 0.001< 0.001
Table 3 Retinal thickness before and after treatment
Group
Number of cases
Retinal thickness (μm)
Prior treatment
One month of treatment
Three months of treatment
Treatment for 6 mo
Control group65637.20 ± 101.96431.12 ± 90.221320.16 ± 88.711,2241.92 ± 70.431,2,3
Observation group65638.39 ± 103.16316.31 ± 86.721221.43 ± 90.221,2170.62 ± 72.341,2,3
t value-0.4926.2166.5355.863
P value0.624< 0.001< 0.001< 0.001
Table 4 Before and after central macular thickness treatment
Group
Number of cases
CMT (μm)
Prior treatment
One month of treatment
Three months of treatment
Treatment for 6 mo
Control group65360.60 ± 41.62307.32 ± 39.421270.38 ± 34.671,2236.71 ± 32.311,2,3
Observation group65357.63 ± 42.51249.31 ± 36.211221.62 ± 31.621,2183.26 ± 33.321,2,3
t value0.4938.9498.6119.175
P value0.623< 0.001< 0.001< 0.001
Table 5 Levels of vascular endothelial growth factor before and after treatment
Group
Number of cases
VEGF (ng/mL)
Prior treatment
One month of treatment
Three months of treatment
Treatment for 6 mo
Control group65423.73 ± 76.35336.73 ± 65.281170.30 ± 41.321,2106.32 ± 10.711,2,3
Observation group65424.32 ± 77.31301.62 ± 63.781110.32 ± 36.721,266.79 ± 10.211,2,3
t value-0.1513.5128.70721.818
P value0.880< 0.001< 0.001< 0.001
Table 6 Interleukin-6 levels before and after treatment
Group
Number of cases
IL-6 (ng/mL)
Prior treatment
One month of treatment
Three months of treatment
Treatment for 6 mo
Control group6576.31 ± 11.7666.31 ± 11.76152.34 ± 8.711,242.91 ± 5.931,2,3
Observation group6575.24 ± 12.0360.12 ± 8.03145.71 ± 7.621,234.73 ± 5.631,2,3
t value0.1964.4763.9818.309
P value0.845< 0.001< 0.001< 0.001
Table 7 Levels of soluble intercellular adhesion molecule-1 before and after treatment
Group
Number of cases
sICAM-1 (ng/mL)
Prior treatment
One month of treatment
Three months of treatment
Treatment for 6 mo
Control group65373.37 ± 83.12313.71 ± 54.621236.42 ± 37.911,2205.71 ± 20.311,2,3
Observation group65376.39 ± 83.83280.18 ± 54.621200.73 ± 37.911,2180.31 ± 20.721,2,3
t value-0.0433.8505.3257.120
P value0.966< 0.001< 0.001< 0.001
Table 8 Levels before and after serum basic fibroblast growth factor treatment
Group
Number of cases
BFGF (g/L)
Prior treatment
One month of treatment
Three months of treatment
Treatment for 6 mo
Control group6552.16 ± 8.1749.31 ± 7.28140.21 ± 6.221,232.41 ± 3.211,2,3
Observation group6553.07 ± 8.0244.12 ± 7.16133.34 ± 5.981,223.62 ± 3.161,2,3
t value-0.2013.6756.60111.661
P value0.841< 0.001< 0.001< 0.001